ALL: Comparing Treatment Options

ALL treatment runs in phases. First comes induction, then consolidation. After that, for many people, comes a long maintenance phase that can run around two years. Ask your team to walk you through this full timeline early. It helps set expectations for how long treatment really lasts.

Induction chemotherapy has one job. It clears leukemia cells from the blood and bone marrow. It combines several chemotherapy drugs. These are given intravenously or by mouth, usually over about a month. A hospital stay is often needed. ALL can spread to the fluid around the brain and spinal cord. To prevent or treat that, treatment also includes intrathecal chemotherapy. This is medicine injected directly into that fluid.

Every new diagnosis should be tested for the Philadelphia chromosome. This is a genetic change found in some ALL. If present, a targeted pill called a tyrosine kinase inhibitor, such as imatinib or dasatinib, is added. That has substantially improved outcomes for Philadelphia-chromosome-positive ALL compared with chemotherapy alone. What the inhibitor is paired with varies: some newer approaches combine it with reduced chemotherapy or with blinatumomab rather than with full-intensity treatment, particularly in older adults.

After induction, consolidation chemotherapy targets any remaining leukemia cells. Maintenance therapy usually follows. It uses lower-intensity chemotherapy over a long stretch, often around two years, to keep the leukemia from returning.

That is a common pattern, not a fixed rule. Several things change it. Your age. The protocol your centre uses. Whether the leukemia is B-cell or T-cell. Whether the Philadelphia chromosome is there. Whether a transplant is planned. How deep the response is on MRD testing. And whether newer drugs such as blinatumomab are in the plan. Your centre gives you the full written schedule. Once it is set, stick to it: stopping maintenance early raises the risk of relapse, and it matters even when you feel completely well. Talk to your team before changing anything.

Blinatumomab is one newer drug option. It connects your T cells to leukemia cells. That lets your immune system attack them. Inotuzumab ozogamicin is an antibody drug that delivers chemotherapy right to leukemia cells. Both are used for relapsed or hard-to-treat ALL. Doctors are also starting to use them earlier in treatment for some patients. CAR T-cell therapy is another option. It works for ALL that has come back after other treatments, especially in children and young adults. Products used include tisagenlecleucel and brexucabtagene autoleucel.

Standard chemotherapy is intensive. It can cause low blood counts, infection risk, and mouth sores. This is worst during induction. Targeted pills for Philadelphia-chromosome-positive ALL are easier to take. But they still need regular monitoring, for side effects like fluid retention or liver changes. Blinatumomab and CAR T-cell therapy both carry a risk of cytokine release syndrome. This is a reaction with fever and low blood pressure. They can also cause neurologic side effects, such as confusion. Both risks need close monitoring, often near a specialized center.

• Was my leukemia tested for the Philadelphia chromosome?
• What does the full induction-to-maintenance timeline look like for me?
• Why is intrathecal chemotherapy part of my plan?
• What symptoms during low blood counts need an urgent call?
• Is CAR T-cell therapy or a clinical trial an option if this returns?

• Call 911 or go to an emergency department if you have a seizure, cannot be woken, or become confused, unsteady, or unable to get your words out. Blinatumomab and CAR T-cell therapy can both cause these nervous system effects.
• Call 911 or go to an emergency department if you have trouble breathing, wheezing, chest pain, or you faint.
• Call your care team right away, day or night, if you have a temperature of 100.4°F (38°C) or higher, chills, a cough or sore throat, or redness where a line enters your body. Your white cells are low during induction, and NCI warns that an infection during cancer treatment can be life threatening and needs urgent medical attention. Do not take a fever reducer before you call, because it can mask the problem. If you cannot reach them quickly, go to an emergency department.
• Call 911 or go to an emergency department if bleeding will not stop — a nosebleed, a gum bleed or a wound that keeps running after firm pressure. Platelets fall along with the other counts during induction, and a bleed that cannot be controlled needs emergency care, not a callback.
• Call your care team the same day if you see blood in your urine or stool, or unusual bruising.
• Call your care team within a day or two if you have mouth sores that stop you eating or drinking, or diarrhea that will not settle.

• National Cancer Institute — Acute Lymphoblastic Leukemia Treatment (PDQ).
• National Cancer Institute — Infection and Neutropenia During Cancer Treatment.
• MedlinePlus — Blinatumomab Injection.
• American Cancer Society — Typical Treatment of Acute Lymphocytic Leukemia, for the length of the maintenance phase.